Utilization and Outcomes of BRCA Genetic Testing and Counseling in a National Commercially Insured Population: The ABOUT Study
- PMID: 26426480
- DOI: 10.1001/jamaoncol.2015.3048
Utilization and Outcomes of BRCA Genetic Testing and Counseling in a National Commercially Insured Population: The ABOUT Study
Erratum in
-
Incomplete Conflict of Interest Disclosure.JAMA Oncol. 2016 Mar;2(3):404. doi: 10.1001/jamaoncol.2016.0048. JAMA Oncol. 2016. PMID: 26847529 No abstract available.
Abstract
Importance: BRCA genetic testing has substantial public health impact, yet little is known of the real-world experiences of the more than 100 000 Americans undergoing testing annually.
Objective: To identify factors associated with use of BRCA testing, assess whether delivery of genetic counseling and testing services adheres to professional guidelines, and measure the impact on patient-reported outcomes.
Design, setting, and participants: The American BRCA Outcomes and Utilization of Testing (ABOUT) Study analyzed data from a consecutive national series of 11 159 women whose clinicians ordered BRCA testing between December 2011 and December 2012. Aetna mailed recruitment information across the United States to commercial health plan members whose clinicians had ordered BRCA testing. A total of 3874 women (34.7%) completed questionnaires. Deidentified clinician-reported data from all respondents and a random sample of 2613 nonrespondents were also analyzed.
Main outcomes and measures: The proportion of eligible participants who met testing criteria and respondents' report of receiving genetic counseling by a genetics clinician and its association with BRCA knowledge, understanding, and satisfaction were assessed.
Results: Among 3628 women respondents whose clinicians ordered comprehensive BRCA testing, most were white non-Hispanic (2502 [69.0%]), college educated (2953 [81.4%]), married (2751 [75.8%]), and had higher incomes (2011 [55.4%]). Approximately 16.4% (596) did not meet testing criteria. Mutations were identified in 161 (5.3%) of these women who received comprehensive testing. Only 1334 (36.8%) reported receiving genetic counseling from a genetics clinician prior to testing; the lowest rates (130 [12.3%]) were among patients of obstetrician/gynecologists. The most commonly reported reason for not receiving this clinical service was lack of clinician recommendation. Those who received it demonstrated greater knowledge about BRCA (mean score difference adjusted for demographics and clinician specialty, β = 0.99 [95% CI, 0.83-1.14]; P < .001) and expressed greater understanding (β = 0.47 [95% CI, 0.41-0.54]; P < .001) and satisfaction (β = 2.21 [95% CI, 1.60-2.81]; P < .001).
Conclusions and relevance: Despite improved patient knowledge, understanding, and satisfaction among patients who receive genetic counseling provided by a genetics clinician, as well as multiple guidelines emphasizing the importance of genetic counseling, most US women undergoing BRCA genetic testing do not receive this clinical service. Lack of physician recommendation is the most commonly reported reason. These findings demonstrate important gaps in clinical genetics services. Recently mandated coverage of genetic counseling services as a preventive service without patient cost sharing should contribute to improving clinical genetics services and associated outcomes in the future.
Comment in
-
Genetic Testing for BRCA Mutations Today and Tomorrow-About the ABOUT Study.JAMA Oncol. 2015 Dec;1(9):1225-6. doi: 10.1001/jamaoncol.2015.3269. JAMA Oncol. 2015. PMID: 26426337 No abstract available.
Similar articles
-
Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.JAMA. 2019 Aug 20;322(7):652-665. doi: 10.1001/jama.2019.10987. JAMA. 2019. PMID: 31429903
-
BRCA Genetic Testing and Receipt of Preventive Interventions Among Women Aged 18-64 Years with Employer-Sponsored Health Insurance in Nonmetropolitan and Metropolitan Areas - United States, 2009-2014.MMWR Surveill Summ. 2017 Sep 8;66(15):1-11. doi: 10.15585/mmwr.ss6615a1. MMWR Surveill Summ. 2017. PMID: 28880857 Free PMC article.
-
Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement.Ann Intern Med. 2014 Feb 18;160(4):271-81. doi: 10.7326/M13-2747. Ann Intern Med. 2014. PMID: 24366376
-
Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force recommendation.Ann Intern Med. 2014 Feb 18;160(4):255-66. doi: 10.7326/M13-1684. Ann Intern Med. 2014. PMID: 24366442 Review.
-
Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force.Ann Intern Med. 2005 Sep 6;143(5):362-79. doi: 10.7326/0003-4819-143-5-200509060-00012. Ann Intern Med. 2005. PMID: 16144895 Review.
Cited by
-
BRCA genetic testing and counseling in breast cancer: how do we meet our patients' needs?NPJ Breast Cancer. 2024 Sep 5;10(1):77. doi: 10.1038/s41523-024-00686-8. NPJ Breast Cancer. 2024. PMID: 39237557 Free PMC article. Review.
-
Information needs persist after genetic counseling and testing for BRCA1/2 and Lynch Syndrome.Breast Cancer Res Treat. 2024 Nov;208(1):19-27. doi: 10.1007/s10549-024-07377-9. Epub 2024 Jul 24. Breast Cancer Res Treat. 2024. PMID: 39046629
-
Cascade genetic testing for hereditary cancer syndromes: a review of barriers and breakthroughs.Fam Cancer. 2024 Jun;23(2):111-120. doi: 10.1007/s10689-024-00373-4. Epub 2024 Mar 26. Fam Cancer. 2024. PMID: 38530571 Review.
-
Randomized trial promoting cancer genetic risk assessment when genetic counseling cost removed: 1-year follow-up.JNCI Cancer Spectr. 2024 Feb 29;8(2):pkae018. doi: 10.1093/jncics/pkae018. JNCI Cancer Spectr. 2024. PMID: 38490263 Free PMC article. Clinical Trial.
-
The ENGAGE study: a 3-arm randomized hybrid type 1 effectiveness and implementation study of an in-home, collaborative PCP model of remote telegenetic services to increase uptake of cancer genetic services in childhood cancer survivors.BMC Health Serv Res. 2024 Feb 28;24(1):253. doi: 10.1186/s12913-024-10586-z. BMC Health Serv Res. 2024. PMID: 38414045 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
